CVS Health Q3 2026 Earnings: Benefits Recovery Drives Higher Adjusted Profit

CVS Health (NYSE: CVS) reported Q3 2026 revenue of $108.4 billion, up 5.4% year over year, while GAAP diluted EPS improved to $1.68 from a loss of $3.13 and adjusted EPS rose to $2.09 from $1.60. Adjusted operating income increased 21.2%, led by insurance margin recovery, while operating cash flow reached $15.3 billion for the first nine months of 2026.

Core Earnings Data

Revenue growth came primarily from the Health Services and Health Care Benefits segments. Underlying profitability improved across all operating segments, with Health Care Benefits accounting for most of the increase in consolidated adjusted operating income.

The GAAP comparison was unusually favorable because Q3 2025 included a $5.7 billion goodwill impairment charge related to Health Care Delivery. Adjusted results, which remove that charge and other specified items, provide a clearer view of the year-over-year operating improvement.

The Q3 2026 reconciliation from GAAP to adjusted results included $425 million of intangible asset amortization and a $193 million Omnicare guarantee, as well as integration costs, capital gains or losses, and related tax effects.

Segment Performance

The segments showed different combinations of revenue and profit growth. Health Services generated the largest revenue increase, but Health Care Benefits produced the most significant improvement in adjusted operating income.

Segment revenue includes intersegment activity and therefore does not add directly to consolidated revenue.

Health Care Benefits

Health Care Benefits was the principal earnings driver. Adjusted operating income rose by $598 million, accounting for about 81% of the $735 million increase in consolidated adjusted operating income. The medical benefit ratio declined by 150 basis points to 91.3%, reflecting improved underlying performance in the Government business.

Government premium revenue increased 8.2% to $28.1 billion, while commercial premium revenue fell 16.9% to $6.5 billion, partly because CVS exited the individual exchange business in 2026. Medical membership was 26.1 million at quarter-end, stable from June 2026 but down from 26.7 million one year earlier.

Health Services

Health Services revenue rose 9.5%, supported by pharmacy drug mix and brand inflation. Pharmacy claims processed increased 1.3% on a 30-day equivalent basis.

Profit growth was more limited than revenue growth. Adjusted operating income increased only 2.7%, while gross margin declined to 5.4% from 5.6% and adjusted operating margin fell to 3.9% from 4.2%. Improved purchasing economics and drug mix were partly offset by continued pharmacy client price improvements.

Pharmacy & Consumer Wellness

Pharmacy & Consumer Wellness revenue declined 2.0% because of regulatory-related price reductions on certain drugs, new generic drug introductions, and reimbursement pressure. These effects more than offset support from prescription volume, drug mix, brand inflation, and the Rite Aid asset acquisitions completed in Q3 2025.

Despite lower revenue, gross profit increased 3.5% and gross margin expanded to 19.2% from 18.1%. Adjusted operating income rose 10.6%, helped by core pharmacy performance and contributions from the Rite Aid assets. Prescriptions filled increased 1.9%, although total same-store sales declined 0.6%.

Profitability, Cash Flow, and Balance Sheet

CVS Health’s adjusted operating margin was approximately 3.9%, up from about 3.4% in the prior-year quarter. This improvement was much smaller than the change in GAAP operating margin because the prior-year period included the goodwill impairment charge.

Operating cash flow for the first nine months of 2026 more than doubled to $15.318 billion from $7.249 billion. The increase reflected the return to GAAP profitability and a $3.556 billion positive contribution from changes in operating assets and liabilities, compared with a $453 million use of cash in the prior-year period.

Cash and cash equivalents increased to $11.738 billion at September 30 from $8.453 billion at the end of 2025. Current and long-term debt totaled approximately $60.7 billion, down about $3.9 billion from year-end. During the nine-month period, CVS repaid $4.057 billion of long-term debt and paid $2.578 billion in dividends.

Full-Year 2026 Guidance

CVS raised its full-year guidance to reflect improved expectations for Health Care Benefits and Pharmacy & Consumer Wellness. The adjusted EPS floor now exceeds the upper end of the previous range, while the GAAP EPS floor raises the former low end but remains below the previous high end. Management maintained a cautious view because of elevated cost trends and potential macroeconomic headwinds.

Recent Insider Transactions

The supplied insider data shows 9,506 shares purchased across six transactions and 3,441,551 shares sold across two transactions during the latest six-month period, resulting in net sales of 3,432,045 shares. The latest individual records include two sales and eight stock awards; stock awards are compensation grants rather than open-market purchases.

The transaction data is descriptive and does not by itself establish insiders’ views on CVS Health’s future performance.

Risks Investors Should Watch

• Medical cost trends: Health Care Benefits improved its medical benefit ratio, but management continues to describe cost trends as elevated. A reversal could pressure the segment’s margin recovery and full-year earnings.
• Health Services margin pressure: Revenue increased much faster than adjusted operating income, while both gross margin and adjusted operating margin declined. Continued client pricing concessions could limit profit conversion.
• Retail pharmacy pricing and reimbursement: Regulatory price reductions, generic introductions, and reimbursement pressure caused Pharmacy & Consumer Wellness revenue to decline despite higher prescription volume.
• Insurance mix and membership: Commercial premium revenue fell sharply following the individual exchange exit, and total medical membership remained below the prior-year level. Continued contraction could offset growth in Government business.
• Macroeconomic sensitivity: CVS explicitly cited potential macroeconomic headwinds when raising guidance, indicating that the higher outlook still incorporates caution for the remainder of the year.

Conclusion

CVS Health’s Q3 2026 results were defined by improved insurance margins rather than revenue growth alone. Health Care Benefits drove most of the adjusted profit increase, Pharmacy & Consumer Wellness expanded margins despite lower revenue, and nine-month cash flow strengthened materially. The main issues to monitor are whether the lower medical benefit ratio is sustainable, whether Health Services can stabilize margins, and how reimbursement and pricing pressure affect the retail pharmacy business.